BROWN RUDNICK LLP for APOTEX CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2009 | $40,000 | Replaced |
| 1st Quarter - Amendment | Apr 20, 2009 | $40,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues relating to antibiotic exclusivity; S. 501 - Fair Prescription Drug Competition Act; H.R. 573 - Relating to marketing of authorized generic drugs; H.R. 1548 - The Pathway to Biosimilars Act; S. 623 & H.R. 1427 - The Promoting Innovation and Access to Life- Savings Medicine Act
Foreign entity interest: Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Copyright/Patent/Trademark CPT
S. 369 - Preserve Access to Affordable Generics Act
Foreign entity interest: Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.